Emerging role of immunotherapy in locally advanced non-small cell lung cancer.
Emerging role of immunotherapy in locally advanced non-small cell lung cancer.
Clin Adv Hematol Oncol. 2020 Apr;18(4):212-217
Authors: Mulherkar R, Grewal AS, Berman AT
Abstract
Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to elucidate the expanding role of immunotherapy.
PMID: 32628649 [PubMed - as supplied by publisher]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | USA Health